ClinicalTrials.gg
RecruitingNCT06547788LAMBDAUpdated Nov 5, 2026

LEFT ATRIAL MONITORING IN PATIENTS BEFORE AND AFTER MITRAL SURGERY - LAMBDA STUDY

An interventional study of Mitral valve repair with creation of an 8 mm inter-atrial shunt in Mitral Regurgitation, Mitral Valve Disease and Heart Failure, sponsored by Ottawa Heart Institute Research Corporation. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Ottawa Heart Institute Research Corporation · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.
Updated Nov 5, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 47 studies in Mitral Valve Insufficiency with a site in Canada — 10 open to participants now, 23 under way, 1 of them phase 3. Mitral Valve Insufficiency · Canada.

Planned enrollment
26th of 35
50 · median 130
Started
2024
with 1 other
No phase
26 of 47
7 open now
Primary completion
2028-01
later than 12 of 22 live
Registered
43rd of 47
by date
Lead sponsor
5 of 47
Ottawa Heart Institute Research Corporation

Among the 47 studies in Mitral Valve Insufficiency with a site in Canada, this one is the 26th largest by planned enrollment of the 35 interventional ones that give a count, is one of 2 that started in 2024, is one of 26 with no phase, reaches primary completion later than 12 of the 22 other live ones, and was the 43rd registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

10 of the 47 studies in Mitral Valve Insufficiency with a site in Canada are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Mitral Valve Insufficiency with a site in Canada, or all of them as a file.
02

Study summary

Mitral valve leakage, or mitral regurgitation (MR), is associated with heart failure symptoms including shortness of breath, fatigue, irregular heart rate. When left untreated, it may cause death. Patients with MR can be divided in two broad groups: those with primary MR, caused by disease of the mitral valve structures, and those with secondary MR, due to dilation of the heart chambers. Our study focuses on patients with primary MR.

The standard treatment for severe symptomatic primary MR is mitral valve surgery, a type of open-heart surgery. The outcomes following this procedure are excellent, however, a subset of patients continue to experience heart failure symptoms after surgery due to very high pressures in the heart, more specifically in the left atrium, which is one of the four heart chambers. This is called functional mitral stenosis (FMS).

Previous studies have shown that creating a small opening between the left and right atria can help relieve the pressure inside the left atrium. We would like to determine whether creating this opening between the two atria at the time of mitral valve surgery can help prevent FMS. To answer this question, we will study two groups of patients who need mitral valve surgery for primary MR. The first group will undergo mitral valve surgery, along with the creation of the opening between the two atria. The second group will undergo mitral valve surgery alone. We will then compare the outcomes between both groups, namely with regards to their heart failure symptoms after open-heart surgery.

03

Conditions studied

  • Mitral Regurgitation
  • Mitral Valve Disease
  • Heart Failure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients ≥18 years of age
  • Severe (4+) symptomatic Carpentier Type II MR due to degenerative disease
  • Planned surgical mitral valve repair
  • Right-to-left atrial pressure gradient ≥ 5 mmHg at baseline
  • Pulmonary vascular resistance ≤ 4 Wood units

Exclusion criteria

Exclusion Criteria:

  • Secondary causes of MR and mixed mitral valve disease
  • Infective endocarditis within 30-days
  • Any prior mitral valve intervention
  • Need for emergency intervention or surgery
  • 2+
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Mitral valve repair with creation of an 8m inter-atrial shunt

    Other: Mitral valve repair with creation of an 8 mm inter-atrial shunt

  • Active comparator
    Mitral valve repair without a shunt

    Other: Mitral valve repair with creation of an 8 mm inter-atrial shunt

Interventions

  • OtherMitral valve repair with creation of an 8 mm inter-atrial shunt

    Mitral valve repair with creation of an 8 mm inter-atrial shunt

06

What researchers measure

Primary outcomes

  1. Feasibility: recruitment rate

    Process, Resources, Management, Scientific

    Time frame: 30 Months

  2. Feasibility: Success rate of intervention

    Process, Resources, Management, Scientific

    Time frame: 30 Months

  3. Feasibility: Study follow-up rate and length

    Process, Resources, Management, Scientific

    Time frame: 30 Months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Jan 2028, 37 months after the start.

Of 144 interventional studies with no phase under Mitral Valve Insufficiency, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 108. This study's planned 37 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Dec 2024, on Nov 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2024
First posted
Aug 9, 2024
StartActual
Dec 19, 2024was Sep 2026
Primary completionEst.
Jan 31, 2028
CompletionEst.
Jan 31, 2030
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 5, 2026
Sites
University of Ottawa Heart Institute is now Recruiting
Nov 5, 2026
Start date
Sep 30, 2026→Dec 19, 2024 (actual)
Nov 5, 2026
Contact
Study contact changed: a•••@ottawaheart.ca · •••7230→n•••@ottawaheart.ca · •••7230. See the current contact
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Not yet recruiting→Recruiting
    University of Ottawa Heart Institute is now Recruiting
    Start date Sep 30, 2026→Dec 19, 2024 (now actual)
    Contact Study contact changed: a•••@ottawaheart.ca · •••7230→n•••@ottawaheart.ca · •••7230. See the current contact
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06547788
Responsible party
Sponsor
First posted
Aug 9, 2024
Start date
Dec 19, 2024
Primary completion
Jan 31, 2028 (estimated)
Completion
Jan 31, 2030 (estimated)
Last update
Nov 5, 2026

Study contacts

Kenza Rahmouni El Idrissi, Dr.
Contact
krahmouni@ottawaheart.ca
613-696-7000
Nahya Awada
Contact
naawada@ottawaheart.ca
613-696-7230
Vincent Chan, Dr.
principal investigator · Ottawa Heart Institute Research Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion